KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $938.9 million.

  • Royalty Pharma's Cash & Equivalents fell 1.17% to $938.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $938.9 million, marking a year-over-year decrease of 1.17%. This contributed to the annual value of $929.0 million for FY2024, which is 94.76% up from last year.
  • Royalty Pharma's Cash & Equivalents amounted to $938.9 million in Q3 2025, which was up 48.59% from $631.9 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash & Equivalents ranged from a high of $2.2 billion in Q2 2023 and a low of $477.0 million during Q4 2023.
  • For the 3-year period, Royalty Pharma's Cash & Equivalents averaged around $1.2 billion, with its median value being $938.9 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 898.21% in 2021, then tumbled by 72.12% in 2023.
  • Over the past 5 years, Royalty Pharma's Cash & Equivalents (Quarterly) stood at $1.5 billion in 2021, then grew by 11.01% to $1.7 billion in 2022, then plummeted by 72.12% to $477.0 million in 2023, then spiked by 94.76% to $929.0 million in 2024, then dropped by 1.17% to $938.9 million in 2025.
  • Its last three reported values are $938.9 million in Q3 2025, $631.9 million for Q2 2025, and $1.1 billion during Q1 2025.